Skip to main content
TipRanks
Go Ultimate75% OFF

Mayne Pharma Group (MAYNF) Q4 2026 Earnings Report

24 Followers

MAYNF Q4 2026 EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.23
Beat/Miss
Missed by -$0.01
One Year Ago EPS
-$0.57

MAYNF Q4 2026 Revenue Results

Actual Revenue
$115.38M
Expected Revenue
$58.16M
Beat/Miss
Beat by +$57.22M
YoY Revenue Growth
-12.02%

Earnings Announcement Details

Quarter
Q4 2026
Date
08/26/2026
Time
After Close
Conference Call
Wednesday, August 26, 2026
MAYNF Upcoming Earnings

Mayne Pharma Group's next earnings date is estimated for February 24, 2027, based on past reporting schedules.

Q4 2026 Earnings Call Audio

MAYNF Q4 2026 Earnings Call
0:00 / 0:00

Q4 2026 Earnings Slide Deck

Q4 2026 Earnings Call Summary

Q4 2026
Earnings Call Date:Aug 26, 2026|% Change Since:66.52%|
Earnings Call Sentiment|Neutral

The call presented a mixed picture: clear operational progress (notably gross margin expansion, successful DistributeRx launch and dermatology margin improvement) and meaningful product‑level growth in women's health (NEXTSTELLIS, BIJUVA, IMVEXXY). However, these positives were offset by weaker headline revenue (‑6%), a 27% decline in underlying EBITDA, significant one‑off and litigation‑related costs, an $11M impact from ANNOVERA returns, and a decline in international contribution (‑38%). Management highlighted a path to margin improvement and capacity expansion that support future upside, but near‑term financial pressures and legal distractions temper the outlook.

Company Guidance

The company guided to a fiscally disciplined FY‑27 focused on growing women's health, scaling DistributeRx and improving margins: management expects women's‑health gross margins to improve year‑on‑year as NEXTSTELLIS coverage expands and ANNOVERA returns (a ~USD11m headwind in FY‑26) are addressed, and highlighted menopause tailwinds (≈75m U.S. women peri/post‑menopause, +1.3m/year; market seen rising ~60% to USD15–25bn by 2030) after the FDA removed the BIJUVA black‑box; product traction cited included BIJUVA net sales +20% to USD15m, IMVEXXY USD29.3m, NEXTSTELLIS USD45.2m and ANNOVERA USD25.7m. On DistributeRx, management signaled near‑term conversion of a “significant percentage” of seven manufacturers covering 13 products (will provide revenue detail at 1H FY‑27), noted ~5,000 new prescribers since launch, a current portfolio of 31 Mayne dermatology and 208 third‑party products, and a major Adelaide Apothecary expansion (up to 2.5m prescriptions p.a., ~USD4m capex) plus a new facility to enable a ~7x capacity increase across two phases. Corporate guidance included no further Cosette scheme costs, litigation expected at normal scale (no quantitative guidance), an expectation that one‑off costs will be lower year‑on‑year, and continued emphasis on channel optimization, profitable portfolio expansion and disciplined, capital‑efficient M&A.

  • Gross Margin Expansion and Stable Gross ProfitGroup gross margin expanded to 64.7%, up 411 basis points year‑on‑year, resulting in gross profit essentially flat at $248.1M despite a 6% decline in revenue.
  • Successful Launch and Rapid Scale of DistributeRxDistributeRx launched in March, materially exceeded expectations with ~5,000 new prescribers since launch; ~60% of U.S. women's health and dermatology volumes moved through non‑traditional channels; platform now carries 31 Mayne products + 208 third‑party products; first third‑party partner signed (Resilia); major two‑phase expansion at Adelaide Apothecary to lift capacity to up to 2.5M prescriptions p.a., with capital investment of ~USD 4M and facility expansion expected to enable a sevenfold increase in capacity over two phases.
  • Women's Health U.S. Momentum and Product GrowthOn a U.S. dollar basis women's health revenue rose ~2% to $118.2M (AUD $174.3M, down 2% FX‑translated). NEXTSTELLIS net sales up 6% (USD $45.2M), BIJUVA net sales up 20% (USD $15M) with prescription growth +26%, and IMVEXXY net sales up 8% (USD $29.3M). Added ~15M additional covered lives in FY'26 to support contraception volumes.
  • Dermatology Margin and Contribution ImprovementDermatology gross profit rose 7% to $88.7M with a 63.9% margin; direct contribution grew 11% to $44.5M, supported by a higher mix of branded products (share increased from ~54% to 58%) and launches of TWYNEO and EPSOLAY.
  • Cash Generation from Underlying BusinessContinuing operations generated positive adjusted operating cash flow of ~$34.5M (operating cash flow broadly stable at $24.9M) and the company closed FY'26 with cash and marketable securities of $80M, underscoring an underlying cash‑generative business after excluding discrete items.
  • International Wins — NEXTSTELLIS PBS Listing and Salisbury InvestmentNEXTSTELLIS secured PBS approval in Australia (listed Oct 1, 2025) with Australian demand cycles rising materially post‑listing; Salisbury facility received an $18M upgrade recognized in export/business awards and supports export and contract manufacturing growth.
  • Management and Balance Sheet ActionsReceived $14.4M from Cosette in satisfaction of court‑ordered legal costs and interest; reclassification of a portion of share‑based retention expense added $2.5M to underlying EBITDA versus prior expectation; executive team and Board strengthened with new CEO (Aaron Gray), new CFO (Griffin Buchanan) and new non‑executive directors.

MAYNF Earnings History

MAYNF earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 24, 20272027 (Q2)-0.14--0.1――
Aug 26, 20262026 (Q4)-0.23-0.24-0.5756.84% (+0.32)
Feb 22, 20262026 (Q2)―-0.10-0.1740.71% (+0.07)
Aug 28, 20252025 (Q4)0.00-0.570-84200.00% (-0.57)
Feb 25, 20252025 (Q2)-0.08-0.17-0.5971.18% (+0.42)
Aug 22, 20242024 (Q4)-0.150.00-1.35100.05% (+1.35)
Feb 25, 20242024 (Q2)-0.31-0.59-0.05-1025.64% (-0.54)
Aug 30, 20232023 (Q4)-0.38-1.35-0.8-67.64% (-0.54)
Feb 27, 20232023 (Q2)-0.54-0.05-0.3785.69% (+0.31)
Aug 25, 20222022 (Q4)-0.19-0.80-0.02-3317.14% (-0.78)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed